AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (de)
EP (1) EP0817626B1 (de)
JP (1) JP3260378B2 (de)
KR (1) KR100286920B1 (de)
CN (1) CN1072485C (de)
AP (1) AP646A (de)
AT (1) ATE172641T1 (de)
AU (1) AU706161B2 (de)
CA (1) CA2216623C (de)
CZ (1) CZ286821B6 (de)
DE (1) DE69600879T2 (de)
DK (1) DK0817626T3 (de)
EA (1) EA000150B1 (de)
ES (1) ES2128846T3 (de)
FR (1) FR06C0014I2 (de)
HU (1) HU224028B1 (de)
IS (1) IS2048B (de)
NO (1) NO315968B1 (de)
NZ (1) NZ304906A (de)
OA (1) OA10515A (de)
PL (1) PL183378B1 (de)
SK (1) SK283883B6 (de)
TR (1) TR199701048T1 (de)
UA (1) UA41446C2 (de)
WO (1) WO1996030010A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100286920B1 (ko) * 1995-03-27 2001-04-16 디. 꼬쉬 장감염에 대한 약물제조용 푸마길올 및 그의 유도체의 용도
EP0799616A1 (de) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Orale Zubereitung enthaltend ein Fumagillolderivat
DE60034770T2 (de) * 1999-02-26 2008-04-30 Sanofi-Aventis Stabile fumagillin-formulierung
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
CN101990441A (zh) * 2007-11-28 2011-03-23 默萨那治疗学股份有限公司 生物相容的生物可降解的烟曲霉素类似物轭合物
US8865746B2 (en) * 2008-07-18 2014-10-21 Zafgen, Inc. Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
MX337575B (es) 2009-10-09 2016-03-10 Zafgen Corp Compuestos de sulfona y métodos para lafabricación y uso de éstos.
JP5827239B2 (ja) 2010-01-08 2015-12-02 ザフゲン，インコーポレイテッド フマギロール型化合物並びにその製造方法及び使用方法
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CA2806221A1 (en) 2010-07-22 2012-01-26 Zafgen, Inc. Tricyclic compounds and methods of making and using same
EP2638023B1 (de) 2010-11-09 2016-09-07 Zafgen, Inc. Crystalline feststoffe von einem metap-2-hemmer, verfahren zu deren herstellung und verwendung
MX2013005989A (es) 2010-11-29 2013-08-21 Zafgen Inc Tratamiento de obesidad utilizando administracion no diaria de 6-o-(4-dimetilaminoetoxi)cinamoil fumagilol.
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
JP5876513B2 (ja) 2011-03-08 2016-03-02 ザフゲン，インコーポレイテッド オキサスピロ［２．５］オクタン誘導体および類似体
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
EP2705035B1 (de) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclische pyrazolsulfonamidverbindungen sowie verfahren und herstellung zu ihrer herstellung
EP2763671A2 (de) 2011-10-03 2014-08-13 Zafgen, Inc. Verfahren zur behandlung von altersbedingten erkrankungen
BR112014017780A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
MX2014008706A (es) 2012-01-18 2015-03-05 Zafgen Inc Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
WO2013169857A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
KR20150079951A (ko) 2012-11-05 2015-07-08 자프겐 인크. 간 질환의 치료 방법
MX2015005733A (es) 2012-11-05 2016-02-10 Zafgen Inc Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
AU2014236528A1 (en) 2013-03-14 2015-09-24 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
WO1992002240A2 (en) * 1990-07-27 1992-02-20 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
KR100286920B1 (ko) * 1995-03-27 2001-04-16 디. 꼬쉬 장감염에 대한 약물제조용 푸마길올 및 그의 유도체의 용도
EP0799616A1 (de) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Orale Zubereitung enthaltend ein Fumagillolderivat
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Also Published As

Publication number Publication date
KR100286920B1 (ko) 2001-04-16
TR199701048T1 (xx) 1998-01-21
HUP9801220A2 (hu) 1999-09-28
PL183378B1 (pl) 2002-06-28
NO974466D0 (no) 1997-09-26
IS4557A (is) 1997-09-11
ATE172641T1 (de) 1998-11-15
OA10515A (fr) 2002-04-24
CA2216623C (en) 2005-05-31
EA199700267A1 (ru) 1998-04-30
FR06C0014I1 (de) 2006-11-17
JP3260378B2 (ja) 2002-02-25
EA000150B1 (ru) 1998-10-29
CA2216623A1 (en) 1996-10-03
CZ286821B6 (en) 2000-07-12
NO974466L (no) 1997-09-26
IS2048B (is) 2005-09-15
ES2128846T3 (es) 1999-05-16
SK283883B6 (sk) 2004-04-06
CN1072485C (zh) 2001-10-10
US5900431A (en) 1999-05-04
HU224028B1 (hu) 2005-05-30
DK0817626T3 (da) 1999-07-12
KR19980703271A (ko) 1998-10-15
CZ304997A3 (en) 1997-12-17
NZ304906A (en) 1999-06-29
HUP9801220A3 (en) 2001-10-29
UA41446C2 (uk) 2001-09-17
EP0817626A2 (de) 1998-01-14
PL322470A1 (en) 1998-02-02
WO1996030010A2 (fr) 1996-10-03
FR06C0014I2 (de) 2006-12-29
SK130797A3 (en) 1998-03-04
DE69600879T2 (de) 1999-06-02
EP0817626B1 (de) 1998-10-28
WO1996030010A3 (fr) 1996-11-28
AU706161B2 (en) 1999-06-10
AU5278696A (en) 1996-10-16
NO315968B1 (no) 2003-11-24
MX9707150A (es) 1998-07-31
DE69600879D1 (de) 1998-12-03
AP9701092A0 (en) 1997-10-31
JPH11506421A (ja) 1999-06-08
CN1179715A (zh) 1998-04-22

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
US4588589A (en) Antidiarrheal compositions and use thereof
CA2193553C (en) Method for treatment of lupus nephritis
AU608853B2 (en) Inhibitors of glycoprotein processing having anti- retroviral activity
JP2004535463A (ja) 心不全処置のための複合治療
EP0190851A1 (de) Entzündungshemmende Zusammensetzung
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
KR100661769B1 (ko) 폐고혈압 치료방법
WO1994005300B1 (en) Use of rapamycin in the treatment of aids
EP0121363A2 (de) Pyrethroid enthaltende pharmazeutische Zubereitungen
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
EP0555302A1 (de) Verfahren zur behandlung von dimyelinierenden krankheiten
EP0338404A1 (de) Verwendung von Megestrol-Acetat zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Aids-verbundener Kachexie
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
US7485642B2 (en) Method for treating septic shock
WO2020242410A1 (en) Pharmaceutical compositions comprising ursodeoxycholic acid as active substance
JPS6045531A (ja) 抗高脂血症剤
US20040044016A1 (en) Antiviral agents
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH0899883A (ja) 膵炎治療剤